Aclidinium bromide vs Aclidinium bromide/formoterol fumarate

Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.

Chronic Obstructive Pulmonary Disease

Shared mechanism: Muscarinic acetylcholine receptor (M3) · full Chronic Obstructive Pulmonary Disease pipeline

Aclidinium bromide · Tudorza Pressair

Marketed by Azurity Pharmaceuticals and partners

Approved in Chronic Obstructive Pulmonary Diseasesmall molecule
Partial signal

NCT00363896 · Phase 3 · completed

The trial randomized 843 participants to double-blind aclidinium or placebo, with trough FEV1 at 12 and 28 weeks, an accepted lung-function endpoint for COPD, as its primary outcome. The registry posts no significance test, but the publication of ACCLAIM/COPD I reports trough FEV1 improvements over placebo of 61 mL and 67 mL at 12 and 28 weeks (both p<0.001).

Reported efficacy

Change From Baseline in Morning Pre-dose (Trough) FEV1 for Aclidinium Bromide (Week 24, morning pre-dose (trough)): Change from baseline in morning pre-dose (trough) FEV1 at Week 24, aclidinium bromide 400 μg vs placebo: LS mean difference 0.134 L (p<0.001); AB 400 μg 0.050 L vs placebo -0.084 L. (met)

Result source: NCT03022097

Aclidinium bromide/formoterol fumarate · Duaklir Pressair

Rights held by Azurity Pharmaceuticals and partners; US product discontinued

Approved in Chronic Obstructive Pulmonary Diseasesmall molecule combination
Partial signal

NCT01437397 · Phase 3 · completed

This was a large randomized, quadruple-blind, placebo- and active-controlled trial with 1,692 randomized participants, using the regulator-accepted clinical lung-function measure FEV1 as its primary endpoint. Results were mixed: the 400/12 μg combination significantly improved post-dose FEV1 versus aclidinium and trough FEV1 versus formoterol, whereas the 400/6 μg combination did not significantly improve trough FEV1 versus formoterol (p=0.133).

Reported efficacy

Change From Baseline in 1-hour Morning Post Forced Expiratory Volume in 1 Second (FEV1) (Week 24, 1-hour morning post-dose); Change From Baseline in Morning Pre-dose (Trough) FEV1 for Aclidinium Bromide/Formoterol Fumarate (Week 24, morning pre-dose (trough)); Change From Baseline in Morning Pre-dose (Trough) FEV1 for Aclidinium Bromide (Week 24, morning pre-dose (trough)): Change From Baseline in 1-hour Morning Post Forced Expiratory Volume in 1 Second (FEV1) (Week 24, 1-hour morning post-dose): AB/FF 400/12 μg 0.248 Litres (Standard Error 0.013) vs AB 400 μg 0.156 Litres (Standard Error 0.013) | FF 12 μg 0.138 Litres (Standard Error 0.013) | Placebo -0.05 Litres (Standard Error 0.013) (met)

Result source: NCT03022097

Results for Chronic Obstructive Pulmonary Disease

Values come from each drug's own ClinicalTrials.gov study. They are from separate trials and patient populations, not a head-to-head comparison. Each result identifies its source trial, phase, arm and timepoint; limitations that apply to a whole cell are marked with a letter and listed once beneath the table. The comparison is deepest for later-stage drugs (phase 3 or approved), which usually have posted results to draw on; early-stage drugs often have none yet.

Key endpointAclidinium bromideAclidinium bromide/​formoterol fumarate
Moderate or severe exacerbations, annualised rate0.4 vs 0.6−0.1 vs placebowk 52 · n 1791NCT01966107—Not reported
Trough FEV1, change0.1 vs -0.1+0.2 vs placebo400/12 μg · wk 24 · n 262NCT03022097
25 other results
  • 0.1 vs -0.1 400 μg · wk 24 · n 265 · Phase 3 · primary NCT03022097
  • 0.1 vs -0.1 400/12 μg · wk 24 · n 262 · Phase 3 · primary NCT03022097
  • 0.1 vs -0.1 400 μg · wk 24 · n 265 · Phase 3 · primary NCT03022097
  • 0.1 vs -0.1 400 μg Bid · wk 24 · n 269 · Phase 3 · primary NCT01001494
  • 0.1 vs -0.0 400/12 μg · wk 24 · n 335 · Phase 3 · primary NCT01437397
  • 0.1 vs -0.0 400/6 μg · wk 24 · n 333 · Phase 3 · primary NCT01437397
  • 0.1 vs -0.1 400/12 μg · wk 24 · n 349 · Phase 3 · primary NCT01462942
  • 0.1 vs -0.1 400/6 μg · wk 24 · n 340 · Phase 3 · primary NCT01462942
  • 1.2 vs 1.2 200 μg once-daily · wk 28 · n 594 · Phase 3 · primary NCT00358436
  • 1.2 vs 1.2 200 μg once-daily · wk 12 · n 594 · Phase 3 · primary NCT00358436
  • 0.1 vs -0.0 400µg · wk 12 · n 190 · Phase 3 · primary NCT00891462
  • 0.1 vs -0.0 400 μg · wk 12 · n 177 · Phase 3 · primary NCT01045161
  • 0.1 vs -0.0 400 μg Bid · wk 12 · n 269 · Phase 3 · primary NCT01001494
  • 0.0 vs -0.1 200 μg Bid · wk 24 · n 277 · Phase 3 · primary NCT01001494
  • 0.1 vs -0.0 200µg · wk 12 · n 184 · Phase 3 · primary NCT00891462
  • 0.0 vs -0.0 200 μg · wk 12 · n 182 · Phase 3 · primary NCT01045161
  • 0.0 vs -0.0 200 μg Bid · wk 12 · n 277 · Phase 3 · primary NCT01001494
  • 0.1 vs 0.1 400/12 μg · wk 24 · n 314 · Phase 3 · primary NCT02796677
  • 0.0 vs -0.1 400/12 μg · wk 52 · n 335 · Phase 3 · secondary NCT01572792
  • 0.0 vs -0.1 400/6 μg · wk 52 · n 333 · Phase 3 · secondary NCT01572792
  • 0.1 vs -0.0 wk 6 · n 86 · Phase 3 · secondary NCT00500318
  • 0.1 vs -0.0 400 μg bid · wk 3 · n 30 · Phase 4 · secondary NCT02153489
  • 0.1 vs -0.0 400 μg Bid · wk 1 · n 73 · Phase 2 · secondary NCT01120093
  • 0.1 vs -0.0 200 μg Bid · wk 1 · n 72 · Phase 2 · secondary NCT01120093
  • 0.1 vs -0.0 100 μg Bid · wk 1 · n 73 · Phase 2 · secondary NCT01120093
0.1 vs -0.0+0.1 vs placebo400/12 μg · wk 24 · n 335NCT01437397
5 other results
  • 0.1 vs -0.0 400/6 μg · wk 24 · n 333 · Phase 3 · primary NCT01437397
  • 0.1 vs -0.1 400/12 μg · wk 24 · n 349 · Phase 3 · primary NCT01462942
  • 0.1 vs -0.1 400/6 μg · wk 24 · n 340 · Phase 3 · primary NCT01462942
  • 0.1 vs -0.1 400/12 μg · wk 24 · n 262 · Phase 3 · primary NCT03022097
  • 0.1 vs -0.1 400/12 μg · wk 24 · n 262 · Phase 3 · primary NCT03022097
SGRQ total, change-8.7 vs -4.7−4 vs placebo400/12 μg · wk 24 · n 262NCT03022097
7 other results
  • -7.6 vs -4.7 400 μg · wk 24 · n 265 · Phase 3 · secondary NCT03022097
  • -6.6 vs -2.2 400/12 μg · wk 24 · n 335 · Phase 3 · secondary NCT01437397
  • -5.9 vs -2.2 400/6 μg · wk 24 · n 333 · Phase 3 · secondary NCT01437397
  • -7.2 vs -6.5 400/12 μg · wk 24 · n 338 · Phase 3 · secondary NCT01462942
  • -8.3 vs -6.5 400/6 μg · wk 24 · n 332 · Phase 3 · secondary NCT01462942
  • -3.6 vs -1.9 400/12 μg · wk 52 · n 335 · Phase 3 · secondary NCT01572792
  • -5.5 vs -1.9 400/6 μg · wk 52 · n 333 · Phase 3 · secondary NCT01572792
-6.6 vs -2.2−4.4 vs placebo400/12 μg · wk 24 · n 335NCT01437397
4 other results
  • -5.9 vs -2.2 400/6 μg · wk 24 · n 333 · Phase 3 · secondary NCT01437397
  • -7.2 vs -6.5 400/12 μg · wk 24 · n 338 · Phase 3 · secondary NCT01462942
  • -8.3 vs -6.5 400/6 μg · wk 24 · n 332 · Phase 3 · secondary NCT01462942
  • -8.7 vs -4.7 400/12 μg · wk 24 · n 262 · Phase 3 · secondary NCT03022097
TDI focal score2.9 vs 2.1+0.8 vs placebo400/12 μg · wk 24 · n 262NCT03022097
5 other results
  • 2.6 vs 2.1 400 μg · wk 24 · n 265 · Phase 3 · secondary NCT03022097
  • 2.0 vs 0.6 400/12 μg · wk 24 · n 335 · Phase 3 · secondary NCT01437397
  • 2.0 vs 0.6 400/6 μg · wk 24 · n 333 · Phase 3 · secondary NCT01437397
  • 2.5 vs 1.2 400/12 μg · wk 24 · n 344 · Phase 3 · secondary NCT01462942
  • 2.4 vs 1.2 400/6 μg · wk 24 · n 333 · Phase 3 · secondary NCT01462942
2.0 vs 0.6+1.4 vs placebo400/12 μg · wk 24 · n 335NCT01437397
5 other results
  • 2.0 vs 0.6 400/6 μg · wk 24 · n 333 · Phase 3 · secondary NCT01437397
  • 2.5 vs 1.2 400/12 μg · wk 24 · n 344 · Phase 3 · secondary NCT01462942
  • 2.4 vs 1.2 400/6 μg · wk 24 · n 333 · Phase 3 · secondary NCT01462942
  • 2.9 vs 2.1 400/12 μg · wk 24 · n 262 · Phase 3 · secondary NCT03022097
  • 1.9 vs 1.9 wk 24 · n 353 · Phase 3 · secondary NCT01908140

Moderate or severe exacerbations, annualised rate

Aclidinium bromide
0.4 vs 0.6−0.1 vs placebowk 52 · n 1791NCT01966107
Aclidinium bromide/​formoterol fumarate
—Not reported

Trough FEV1, change

Aclidinium bromide
0.1 vs -0.1+0.2 vs placebo400/12 μg · wk 24 · n 262NCT03022097
25 other results
  • 0.1 vs -0.1 400 μg · wk 24 · n 265 · Phase 3 · primary NCT03022097
  • 0.1 vs -0.1 400/12 μg · wk 24 · n 262 · Phase 3 · primary NCT03022097
  • 0.1 vs -0.1 400 μg · wk 24 · n 265 · Phase 3 · primary NCT03022097
  • 0.1 vs -0.1 400 μg Bid · wk 24 · n 269 · Phase 3 · primary NCT01001494
  • 0.1 vs -0.0 400/12 μg · wk 24 · n 335 · Phase 3 · primary NCT01437397
  • 0.1 vs -0.0 400/6 μg · wk 24 · n 333 · Phase 3 · primary NCT01437397
  • 0.1 vs -0.1 400/12 μg · wk 24 · n 349 · Phase 3 · primary NCT01462942
  • 0.1 vs -0.1 400/6 μg · wk 24 · n 340 · Phase 3 · primary NCT01462942
  • 1.2 vs 1.2 200 μg once-daily · wk 28 · n 594 · Phase 3 · primary NCT00358436
  • 1.2 vs 1.2 200 μg once-daily · wk 12 · n 594 · Phase 3 · primary NCT00358436
  • 0.1 vs -0.0 400µg · wk 12 · n 190 · Phase 3 · primary NCT00891462
  • 0.1 vs -0.0 400 μg · wk 12 · n 177 · Phase 3 · primary NCT01045161
  • 0.1 vs -0.0 400 μg Bid · wk 12 · n 269 · Phase 3 · primary NCT01001494
  • 0.0 vs -0.1 200 μg Bid · wk 24 · n 277 · Phase 3 · primary NCT01001494
  • 0.1 vs -0.0 200µg · wk 12 · n 184 · Phase 3 · primary NCT00891462
  • 0.0 vs -0.0 200 μg · wk 12 · n 182 · Phase 3 · primary NCT01045161
  • 0.0 vs -0.0 200 μg Bid · wk 12 · n 277 · Phase 3 · primary NCT01001494
  • 0.1 vs 0.1 400/12 μg · wk 24 · n 314 · Phase 3 · primary NCT02796677
  • 0.0 vs -0.1 400/12 μg · wk 52 · n 335 · Phase 3 · secondary NCT01572792
  • 0.0 vs -0.1 400/6 μg · wk 52 · n 333 · Phase 3 · secondary NCT01572792
  • 0.1 vs -0.0 wk 6 · n 86 · Phase 3 · secondary NCT00500318
  • 0.1 vs -0.0 400 μg bid · wk 3 · n 30 · Phase 4 · secondary NCT02153489
  • 0.1 vs -0.0 400 μg Bid · wk 1 · n 73 · Phase 2 · secondary NCT01120093
  • 0.1 vs -0.0 200 μg Bid · wk 1 · n 72 · Phase 2 · secondary NCT01120093
  • 0.1 vs -0.0 100 μg Bid · wk 1 · n 73 · Phase 2 · secondary NCT01120093
Aclidinium bromide/​formoterol fumarate
0.1 vs -0.0+0.1 vs placebo400/12 μg · wk 24 · n 335NCT01437397
5 other results
  • 0.1 vs -0.0 400/6 μg · wk 24 · n 333 · Phase 3 · primary NCT01437397
  • 0.1 vs -0.1 400/12 μg · wk 24 · n 349 · Phase 3 · primary NCT01462942
  • 0.1 vs -0.1 400/6 μg · wk 24 · n 340 · Phase 3 · primary NCT01462942
  • 0.1 vs -0.1 400/12 μg · wk 24 · n 262 · Phase 3 · primary NCT03022097
  • 0.1 vs -0.1 400/12 μg · wk 24 · n 262 · Phase 3 · primary NCT03022097

SGRQ total, change

Aclidinium bromide
-8.7 vs -4.7−4 vs placebo400/12 μg · wk 24 · n 262NCT03022097
7 other results
  • -7.6 vs -4.7 400 μg · wk 24 · n 265 · Phase 3 · secondary NCT03022097
  • -6.6 vs -2.2 400/12 μg · wk 24 · n 335 · Phase 3 · secondary NCT01437397
  • -5.9 vs -2.2 400/6 μg · wk 24 · n 333 · Phase 3 · secondary NCT01437397
  • -7.2 vs -6.5 400/12 μg · wk 24 · n 338 · Phase 3 · secondary NCT01462942
  • -8.3 vs -6.5 400/6 μg · wk 24 · n 332 · Phase 3 · secondary NCT01462942
  • -3.6 vs -1.9 400/12 μg · wk 52 · n 335 · Phase 3 · secondary NCT01572792
  • -5.5 vs -1.9 400/6 μg · wk 52 · n 333 · Phase 3 · secondary NCT01572792
Aclidinium bromide/​formoterol fumarate
-6.6 vs -2.2−4.4 vs placebo400/12 μg · wk 24 · n 335NCT01437397
4 other results
  • -5.9 vs -2.2 400/6 μg · wk 24 · n 333 · Phase 3 · secondary NCT01437397
  • -7.2 vs -6.5 400/12 μg · wk 24 · n 338 · Phase 3 · secondary NCT01462942
  • -8.3 vs -6.5 400/6 μg · wk 24 · n 332 · Phase 3 · secondary NCT01462942
  • -8.7 vs -4.7 400/12 μg · wk 24 · n 262 · Phase 3 · secondary NCT03022097

TDI focal score

Aclidinium bromide
2.9 vs 2.1+0.8 vs placebo400/12 μg · wk 24 · n 262NCT03022097
5 other results
  • 2.6 vs 2.1 400 μg · wk 24 · n 265 · Phase 3 · secondary NCT03022097
  • 2.0 vs 0.6 400/12 μg · wk 24 · n 335 · Phase 3 · secondary NCT01437397
  • 2.0 vs 0.6 400/6 μg · wk 24 · n 333 · Phase 3 · secondary NCT01437397
  • 2.5 vs 1.2 400/12 μg · wk 24 · n 344 · Phase 3 · secondary NCT01462942
  • 2.4 vs 1.2 400/6 μg · wk 24 · n 333 · Phase 3 · secondary NCT01462942
Aclidinium bromide/​formoterol fumarate
2.0 vs 0.6+1.4 vs placebo400/12 μg · wk 24 · n 335NCT01437397
5 other results
  • 2.0 vs 0.6 400/6 μg · wk 24 · n 333 · Phase 3 · secondary NCT01437397
  • 2.5 vs 1.2 400/12 μg · wk 24 · n 344 · Phase 3 · secondary NCT01462942
  • 2.4 vs 1.2 400/6 μg · wk 24 · n 333 · Phase 3 · secondary NCT01462942
  • 2.9 vs 2.1 400/12 μg · wk 24 · n 262 · Phase 3 · secondary NCT03022097
  • 1.9 vs 1.9 wk 24 · n 353 · Phase 3 · secondary NCT01908140
  1. Each cell is from that drug's own trial. Trials differ in population, design and timepoint; this is not a head-to-head comparison.
  2. An empty cell names why: Not posted (a completed Phase 3 here has no posted results yet), Trial running, Pending review (we hold the result and are checking it) or Not reported.
2 other shared endpoints and safety

Coverage. Aclidinium bromide: 6 of 6 rows · Aclidinium bromide/formoterol fumarate: 6 of 6 rows. A dash means no reviewed, structured value is available for that endpoint in this indication.

Reported metricAclidinium bromideAclidinium bromide/​formoterol fumarate
Rows use multiple source trials
FEV1 Change 1h
absolute change · L
0.156 vs -0.05 placebo L @ 24wk400 μga,b,c
NCT03022097 · Phase 3 · Chronic Obstructive Pulmonary Disease · phase 3
show 1 more dose
0.248 vs -0.05 placebo L @ 24wk400/12 μg
NCT03022097 · Phase 3 · Chronic Obstructive Pulmonary Disease · phase 3
0.247 vs -0.037 placebo L @ 24wk400/12 μga,b,c
NCT01437397 · Phase 3 · Chronic Obstructive Pulmonary Disease · phase 3
show 1 more dose
0.226 vs -0.037 placebo L @ 24wk400/6 μg
NCT01437397 · Phase 3 · Chronic Obstructive Pulmonary Disease · phase 3
FEV1 Peak
absolute change · L
0.225 vs 0.008 placebo L @ 24wk400 μga,c
NCT03022097 · Phase 3 · Chronic Obstructive Pulmonary Disease · phase 3
show 1 more dose
0.324 vs 0.008 placebo L @ 24wk400/12 μg
NCT03022097 · Phase 3 · Chronic Obstructive Pulmonary Disease · phase 3
0.324 vs 0.008 placebo L @ 24wk400/12 μgc
NCT03022097 · Phase 3 · combination · Chronic Obstructive Pulmonary Disease · phase 3
1 other source trial
1.655 vs 1.562 Salmeterol / Fluticasone L @ 24wk
NCT01908140 · Phase 3 · Chronic Obstructive Pulmonary Disease · phase 3
Dropout rate
14.2%200 μg Once-dailyd
NCT00363896 · Phase 3 · monotherapy
show 34 more results
25.7%200 μg once-daily
NCT00358436 · Phase 3 · monotherapy
7.1%400 μg
NCT03022097 · Phase 3 · Chronic Obstructive Pulmonary Disease · phase 3
7.9%400/12 μg
NCT03022097 · Phase 3 · Chronic Obstructive Pulmonary Disease · phase 3
—400 μg Bid
NCT01120093 · Phase 2
—200 μg Bid
NCT01120093 · Phase 2
—100 μg Bid
NCT01120093 · Phase 2
12.6%400µg
NCT00891462 · Phase 3
17.8%200µg
NCT00891462 · Phase 3
—400 μg
NCT01045161 · Phase 3
—400 μg
NCT01045161 · Phase 3
—200 μg
NCT01045161 · Phase 3
—200 μg to 400 μg
NCT01045161 · Phase 3
6.3%400 μg Bid
NCT01001494 · Phase 3
8.7%200 μg Bid
NCT01001494 · Phase 3
44.3%
NCT01966107 · Phase 4
4.4%400 μg
NCT02375724 · Phase 4 · registry result, not featured evidence
—400 μg bid
NCT02153489 · Phase 4 · registry result, not featured evidence
—400/12 μg
NCT02796677 · Phase 3 · registry result, not featured evidence
19.5%400/12 μg
NCT01572792 · Phase 3 · registry result, not featured evidence
18.3%400/6 μg
NCT01572792 · Phase 3 · registry result, not featured evidence
19.5%400/12 μg
NCT01437397 · Phase 3 · registry result, not featured evidence · Chronic Obstructive Pulmonary Disease · phase 3
18.3%400/6 μg
NCT01437397 · Phase 3 · registry result, not featured evidence · Chronic Obstructive Pulmonary Disease · phase 3
8.8%400/12 μg
NCT01462942 · Phase 3 · registry result, not featured evidence
10.5%400/6 μg
NCT01462942 · Phase 3 · registry result, not featured evidence
—400 μg BID
NCT01471171 · Phase 3 · registry result, not featured evidence
2.9%400 µg BID
NCT01462929 · Phase 3 · registry result, not featured evidence
44.7%400µg
NCT01044459 · Phase 3 · registry result, not featured evidence
42.6%200µg
NCT01044459 · Phase 3 · registry result, not featured evidence
—400 μg
NCT00970268 · Phase 3 · registry result, not featured evidence
—400 μg
NCT00970268 · Phase 3 · registry result, not featured evidence
—200 μg
NCT00970268 · Phase 3 · registry result, not featured evidence
—200 μg
NCT00970268 · Phase 3 · registry result, not featured evidence
5.8%
NCT00500318 · Phase 3 · registry result, not featured evidence
—400 μg Bid
NCT00868231 · Phase 2 · registry result, not featured evidence
19.5%400/12 μge
NCT01437397 · Phase 3 · Chronic Obstructive Pulmonary Disease · phase 3
show 7 more results
18.3%400/6 μg
NCT01437397 · Phase 3 · Chronic Obstructive Pulmonary Disease · phase 3
7.9%400/12 μg
NCT03022097 · Phase 3 · combination · Chronic Obstructive Pulmonary Disease · phase 3
14.1%
NCT01908140 · Phase 3 · Chronic Obstructive Pulmonary Disease · phase 3
8.8%400/12 μg
NCT01462942 · Phase 3
10.5%400/6 μg
NCT01462942 · Phase 3
32.4%400 μg/12 μg
NCT01437540 · Phase 3 · registry result, not featured evidence
5%400/12 BID
NCT03276078 · Phase 2 · registry result, not featured evidence
Discontinued due to AEs
3.8%200 μg Once-dailyd
NCT00363896 · Phase 3 · monotherapy
show 34 more results
4.8%200 μg once-daily
NCT00358436 · Phase 3 · monotherapy
1.5%400 μg
NCT03022097 · Phase 3 · Chronic Obstructive Pulmonary Disease · phase 3
1.1%400/12 μg
NCT03022097 · Phase 3 · Chronic Obstructive Pulmonary Disease · phase 3
—400 μg Bid
NCT01120093 · Phase 2
—200 μg Bid
NCT01120093 · Phase 2
—100 μg Bid
NCT01120093 · Phase 2
3.7%400µg
NCT00891462 · Phase 3
4.3%200µg
NCT00891462 · Phase 3
—400 μg
NCT01045161 · Phase 3
—400 μg
NCT01045161 · Phase 3
—200 μg
NCT01045161 · Phase 3
—200 μg to 400 μg
NCT01045161 · Phase 3
1.5%400 μg Bid
NCT01001494 · Phase 3
2.9%200 μg Bid
NCT01001494 · Phase 3
—
NCT01966107 · Phase 4
1.5%400 μg
NCT02375724 · Phase 4 · registry result, not featured evidence
—400 μg bid
NCT02153489 · Phase 4 · registry result, not featured evidence
—400/12 μg
NCT02796677 · Phase 3 · registry result, not featured evidence
6.2%400/12 μg
NCT01572792 · Phase 3 · registry result, not featured evidence
6.5%400/6 μg
NCT01572792 · Phase 3 · registry result, not featured evidence
6.2%400/12 μg
NCT01437397 · Phase 3 · registry result, not featured evidence · Chronic Obstructive Pulmonary Disease · phase 3
6.5%400/6 μg
NCT01437397 · Phase 3 · registry result, not featured evidence · Chronic Obstructive Pulmonary Disease · phase 3
3.1%400/12 μg
NCT01462942 · Phase 3 · registry result, not featured evidence
2.6%400/6 μg
NCT01462942 · Phase 3 · registry result, not featured evidence
—400 μg BID
NCT01471171 · Phase 3 · registry result, not featured evidence
1.8%400 µg BID
NCT01462929 · Phase 3 · registry result, not featured evidence
6.8%400µg
NCT01044459 · Phase 3 · registry result, not featured evidence
7.1%200µg
NCT01044459 · Phase 3 · registry result, not featured evidence
—400 μg
NCT00970268 · Phase 3 · registry result, not featured evidence
—400 μg
NCT00970268 · Phase 3 · registry result, not featured evidence
—200 μg
NCT00970268 · Phase 3 · registry result, not featured evidence
—200 μg
NCT00970268 · Phase 3 · registry result, not featured evidence
3.5%
NCT00500318 · Phase 3 · registry result, not featured evidence
—400 μg Bid
NCT00868231 · Phase 2 · registry result, not featured evidence
6.2%400/12 μge
NCT01437397 · Phase 3 · Chronic Obstructive Pulmonary Disease · phase 3
show 7 more results
6.5%400/6 μg
NCT01437397 · Phase 3 · Chronic Obstructive Pulmonary Disease · phase 3
1.1%400/12 μg
NCT03022097 · Phase 3 · combination · Chronic Obstructive Pulmonary Disease · phase 3
4.7%
NCT01908140 · Phase 3 · Chronic Obstructive Pulmonary Disease · phase 3
3.1%400/12 μg
NCT01462942 · Phase 3
2.6%400/6 μg
NCT01462942 · Phase 3
6.6%400 μg/12 μg
NCT01437540 · Phase 3 · registry result, not featured evidence
5%400/12 BID
NCT03276078 · Phase 2 · registry result, not featured evidence
Serious AEs
8%200 μg Once-dailyd
NCT00363896 · Phase 3 · monotherapy
show 34 more results
10.3%200 μg once-daily
NCT00358436 · Phase 3 · monotherapy
7.9%400 μg
NCT03022097 · Phase 3 · Chronic Obstructive Pulmonary Disease · phase 3
7.2%400/12 μg
NCT03022097 · Phase 3 · Chronic Obstructive Pulmonary Disease · phase 3
1.4%400 μg Bid
NCT01120093 · Phase 2
1.4%200 μg Bid
NCT01120093 · Phase 2
0%100 μg Bid
NCT01120093 · Phase 2
3.2%400µg
NCT00891462 · Phase 3
4.3%200µg
NCT00891462 · Phase 3
4.5%400 μg
NCT01045161 · Phase 3
9.5%400 μg
NCT01045161 · Phase 3
6%200 μg
NCT01045161 · Phase 3
13%200 μg to 400 μg
NCT01045161 · Phase 3
5.6%400 μg Bid
NCT01001494 · Phase 3
4.3%200 μg Bid
NCT01001494 · Phase 3
22.8%
NCT01966107 · Phase 4
1.5%400 μg
NCT02375724 · Phase 4 · registry result, not featured evidence
0%400 μg bid
NCT02153489 · Phase 4 · registry result, not featured evidence
7.3%400/12 μg
NCT02796677 · Phase 3 · registry result, not featured evidence
7.7%400/12 μg
NCT01572792 · Phase 3 · registry result, not featured evidence
6.9%400/6 μg
NCT01572792 · Phase 3 · registry result, not featured evidence
5.7%400/12 μg
NCT01437397 · Phase 3 · registry result, not featured evidence · Chronic Obstructive Pulmonary Disease · phase 3
5.4%400/6 μg
NCT01437397 · Phase 3 · registry result, not featured evidence · Chronic Obstructive Pulmonary Disease · phase 3
6%400/12 μg
NCT01462942 · Phase 3 · registry result, not featured evidence
4.7%400/6 μg
NCT01462942 · Phase 3 · registry result, not featured evidence
0%400 μg BID
NCT01471171 · Phase 3 · registry result, not featured evidence
1.8%400 µg BID
NCT01462929 · Phase 3 · registry result, not featured evidence
10%400µg
NCT01044459 · Phase 3 · registry result, not featured evidence
9.3%200µg
NCT01044459 · Phase 3 · registry result, not featured evidence
12.3%400 μg
NCT00970268 · Phase 3 · registry result, not featured evidence
15.2%400 μg
NCT00970268 · Phase 3 · registry result, not featured evidence
14%200 μg
NCT00970268 · Phase 3 · registry result, not featured evidence
15.9%200 μg
NCT00970268 · Phase 3 · registry result, not featured evidence
2.3%
NCT00500318 · Phase 3 · registry result, not featured evidence
0%400 μg Bid
NCT00868231 · Phase 2 · registry result, not featured evidence
5.7%400/12 μge
NCT01437397 · Phase 3 · Chronic Obstructive Pulmonary Disease · phase 3
show 7 more results
5.4%400/6 μg
NCT01437397 · Phase 3 · Chronic Obstructive Pulmonary Disease · phase 3
7.2%400/12 μg
NCT03022097 · Phase 3 · combination · Chronic Obstructive Pulmonary Disease · phase 3
7.5%
NCT01908140 · Phase 3 · Chronic Obstructive Pulmonary Disease · phase 3
6%400/12 μg
NCT01462942 · Phase 3
4.7%400/6 μg
NCT01462942 · Phase 3
9.7%400 μg/12 μg
NCT01437540 · Phase 3 · registry result, not featured evidence
5%400/12 BID
NCT03276078 · Phase 2 · registry result, not featured evidence
Most frequent reported AEs
200 μg Once-dailyd
nasopharyngitis 16.3% (placebo 14.4%)
headache 11.3% (placebo 12.5%)
back pain 4.8% (placebo 4.6%)
NCT00363896 · Phase 3 · monotherapy
show 34 more results
200 μg once-daily
headache 14.2% (placebo 12.7%)
nasopharyngitis 12.7% (placebo 11.3%)
upper respiratory tract infection 10.8% (placebo 9.8%)
NCT00358436 · Phase 3 · monotherapy
400 μg
upper respiratory tract infection 9.4% (placebo 8.9%)
chronic obstructive pulmonary disease 7.9% (placebo 13%)
NCT03022097 · Phase 3 · Chronic Obstructive Pulmonary Disease · phase 3
400/12 μg
upper respiratory tract infection 11.8% (placebo 8.9%)
chronic obstructive pulmonary disease 9.5% (placebo 13%)
NCT03022097 · Phase 3 · Chronic Obstructive Pulmonary Disease · phase 3
400 μg Bid
headache 6.8% (placebo 1.3%)
NCT01120093 · Phase 2
200 μg Bid
headache 5.5% (placebo 1.3%)
NCT01120093 · Phase 2
100 μg Bid
headache 5.5% (placebo 1.3%)
NCT01120093 · Phase 2
400µg
chronic obstructive pulmonary disease 7.4% (placebo 12.4%)
NCT00891462 · Phase 3
200µg
chronic obstructive pulmonary disease 9.2% (placebo 12.4%)
NCT00891462 · Phase 3
400 μg
copd exacerbation 13% (placebo 11.5%)
upper respiratory tract infection 1.7% (placebo 0.5%)
nasopharyngitis 1.1% (placebo 0%)
NCT01045161 · Phase 3
400 μg
copd exacerbation 27.9% (placebo 11.5%)
upper respiratory tract infection 5.4% (placebo 0.5%)
nasopharyngitis 4.1% (placebo 0%)
NCT01045161 · Phase 3
200 μg
copd exacerbation 8.7% (placebo 11.5%)
upper respiratory tract infection 1.6% (placebo 0.5%)
nasopharyngitis 1.1% (placebo 0%)
NCT01045161 · Phase 3
200 μg to 400 μg
copd exacerbation 22.7% (placebo 11.5%)
nasopharyngitis 5.8% (placebo 0%)
upper respiratory tract infection 5.8% (placebo 0.5%)
NCT01045161 · Phase 3
400 μg Bid
chronic obstructivce pulmonary disease 14.1% (placebo 20.5%)
headache 12.3% (placebo 8.1%)
nasopharyngitis 11.2% (placebo 8.4%)
NCT01001494 · Phase 3
200 μg Bid
chronic obstructivce pulmonary disease 15.9% (placebo 20.5%)
nasopharyngitis 11.6% (placebo 8.4%)
headache 10.8% (placebo 8.1%)
NCT01001494 · Phase 3
urinary tract infection 5% (placebo 4.7%)
upper respiratory tract infection 4.8% (placebo 5.6%)
viral upper respiratory tract infection 4.4% (placebo 3.7%)
NCT01966107 · Phase 4
400 μg
headache 5.2% (placebo 9.7%)
nasopharyngitis 3% (placebo 6.7%)
NCT02375724 · Phase 4 · registry result, not featured evidence
400 μg bid
erythema 10% (placebo 0%)
NCT02153489 · Phase 4 · registry result, not featured evidence
400/12 μg
chronic obstructive pulmonary 15.6%
nasopharyngitis 11.5%
headache 5.1%
NCT02796677 · Phase 3 · registry result, not featured evidence
400/12 μg
chronic obstructive pulmonary disease 20.3% (placebo 15.8%)
urinary tract infection 8.2% (placebo 5.5%)
nasopharyngitis 7.7% (placebo 4.8%)
NCT01572792 · Phase 3 · registry result, not featured evidence
400/6 μg
chronic obstructive pulmonary disease 22.1% (placebo 15.8%)
nasopharyngitis 6.9% (placebo 4.8%)
urinary tract infection 6.4% (placebo 5.5%)
NCT01572792 · Phase 3 · registry result, not featured evidence
400/12 μg
chronic obstructive pulmonary disease 15.2% (placebo 17.5%)
cough 5.1% (placebo 3.6%)
nasopharyngitis 4.8% (placebo 3.6%)
NCT01437397 · Phase 3 · registry result, not featured evidence · Chronic Obstructive Pulmonary Disease · phase 3
400/6 μg
chronic obstructive pulmonary disease 14.7% (placebo 17.5%)
nasopharyngitis 5.1% (placebo 3.6%)
cough 3.9% (placebo 3.6%)
NCT01437397 · Phase 3 · registry result, not featured evidence · Chronic Obstructive Pulmonary Disease · phase 3
400/12 μg
chronic obstructive pulmonary disease 8.6% (placebo 11.9%)
nasopharyngitis 7.8% (placebo 7.2%)
headache 7.5% (placebo 8.2%)
NCT01462942 · Phase 3 · registry result, not featured evidence
400/6 μg
chronic obstructive pulmonary disease 9.4% (placebo 11.9%)
nasopharyngitis 7.9% (placebo 7.2%)
headache 7.1% (placebo 8.2%)
NCT01462942 · Phase 3 · registry result, not featured evidence
400 μg BID
nasopharyngitis 6.3% (placebo 3.7%)
NCT01471171 · Phase 3 · registry result, not featured evidence
400 µg BID
nasopharyngitis 6.4% (placebo 2.4%)
headache 3.5% (placebo 4.7%)
NCT01462929 · Phase 3 · registry result, not featured evidence
400µg
chronic obstructive pulmonary disease 19.9%
NCT01044459 · Phase 3 · registry result, not featured evidence
200µg
chronic obstructive pulmonary disease 19.3%
NCT01044459 · Phase 3 · registry result, not featured evidence
400 μg
chronic obstructive pulmonary disorder 22.6%
nasopharyngitis 9.4%
urinary tract infection 7.5%
NCT00970268 · Phase 3 · registry result, not featured evidence
400 μg
chronic obstructive pulmonary disorder 30.4%
contusion 10.9%
cough 8.7%
NCT00970268 · Phase 3 · registry result, not featured evidence
200 μg
chronic obstructive pulmonary disorder 24.7%
nasopharyngitis 8.6%
back pain 7.5%
NCT00970268 · Phase 3 · registry result, not featured evidence
200 μg
chronic obstructive pulmonary disorder 36.4%
sinusitis 11.4%
upper respiratory tract infection 11.4%
NCT00970268 · Phase 3 · registry result, not featured evidence
cough 5.8% (placebo 3.2%)
headache 5.8% (placebo 7.4%)
upper respiratory tract infection 5.8% (placebo 2.1%)
NCT00500318 · Phase 3 · registry result, not featured evidence
400 μg Bid
diarrhoea 6.9% (placebo 0%)
chronic obstructive pulmonary disease 0% (placebo 10%)
NCT00868231 · Phase 2 · registry result, not featured evidence
400/12 μge
chronic obstructive pulmonary disease 15.2% (placebo 17.5%)
cough 5.1% (placebo 3.6%)
nasopharyngitis 4.8% (placebo 3.6%)
NCT01437397 · Phase 3 · Chronic Obstructive Pulmonary Disease · phase 3
show 7 more results
400/6 μg
chronic obstructive pulmonary disease 14.7% (placebo 17.5%)
nasopharyngitis 5.1% (placebo 3.6%)
cough 3.9% (placebo 3.6%)
NCT01437397 · Phase 3 · Chronic Obstructive Pulmonary Disease · phase 3
400/12 μg
upper respiratory tract infection 11.8% (placebo 8.9%)
chronic obstructive pulmonary disease 9.5% (placebo 13%)
NCT03022097 · Phase 3 · combination · Chronic Obstructive Pulmonary Disease · phase 3
chronic obstructive pulmonary disease 15%
headache 6%
nasopharyngitis 5.6%
NCT01908140 · Phase 3 · Chronic Obstructive Pulmonary Disease · phase 3
400/12 μg
chronic obstructive pulmonary disease 8.6% (placebo 11.9%)
nasopharyngitis 7.8% (placebo 7.2%)
headache 7.5% (placebo 8.2%)
NCT01462942 · Phase 3
400/6 μg
chronic obstructive pulmonary disease 9.4% (placebo 11.9%)
nasopharyngitis 7.9% (placebo 7.2%)
headache 7.1% (placebo 8.2%)
NCT01462942 · Phase 3
400 μg/12 μg
chronic obstructive pulmonary disease 27%
urinary tract infection 6.6%
nasopharyngitis 6.4%
NCT01437540 · Phase 3 · registry result, not featured evidence
400/12 BID
protein urine present 15%
NCT03276078 · Phase 2 · registry result, not featured evidence

Notes

  1. aThis study reports multiple eligible drug arms; no representative arm has been reviewed.
  2. bPopulation context differs: baseline_threshold differs (fev1_pct_predicted<80 versus fev1_pct_predicted<80, fev1_pct_predicted>=30).
  3. cTreatment context has not been resolved for both arms.
  4. dPopulation comparability has not been reviewed for 31 of these studies.
  5. ePopulation comparability has not been reviewed for 4 of these studies.

Reported by one asset only

Endpoints only one of the selected assets measured, so there is nothing to compare them against.

Aclidinium bromide

FEV1 Trough 1.422 vs 1.356 placebo L @ 28wk200 μg Once-daily
absolute value · L
NCT00363896 · Phase 3 · monotherapy
show 1 more result
1.428 vs 1.366 placebo L @ 12wk200 μg Once-daily
NCT00363896 · Phase 3 · monotherapy
Time to First Exacerbation NA vs NA placebo months @ 52wk200 μg Once-daily
time to event · months
NCT00363896 · Phase 3 · monotherapy
SGRQ 57.3% (n=269) vs 41% (n=271) placebo @ 24wk400 μg Bid
responder rate · % of participants
Yes (% Patients with 4-unit decrease)
NCT01001494 · Phase 3
show 3 more results
48.1% (n=591) vs 39.5% (n=200) placebo @ 52wk200 μg Once-daily
Yes (% Patients with 4-unit decrease)
NCT00363896 · Phase 3 · monotherapy
39% (n=574) vs 32.8% (n=195) placebo @ 52wk200 μg once-daily
Yes (% Patients with 4-unit decrease)
NCT00358436 · Phase 3 · monotherapy
56% (n=275) vs 41% (n=271) placebo @ 24wk200 μg Bid
Yes (% Patients with 4-unit decrease)
NCT01001494 · Phase 3
Time to First Moderate or Severe Exacerbation NA vs NA placebo months @ 52wk200 μg once-daily
time to event · months
NCT00358436 · Phase 3 · monotherapy
FEV1 AUC0-12h 0.183 vs -0.026 placebo L @ 1wk400 μg Bid
absolute change · L
NCT01120093 · Phase 2
show 4 more results
0.236 vs 0.015 placebo L @ 2.142857142857143wk400 μg Bid
NCT00868231 · Phase 2 · registry result, not featured evidence
0.23 vs 0.016 placebo L @ 0.142857142857143wk400 μg Bid
NCT00868231 · Phase 2 · registry result, not featured evidence
0.151 vs -0.026 placebo L @ 1wk200 μg Bid
NCT01120093 · Phase 2
0.128 vs -0.026 placebo L @ 1wk100 μg Bid
NCT01120093 · Phase 2
FEV1 AUC 12-24h 0.086 vs -0.103 placebo L @ 1wk400 μg Bid
absolute change · L
NCT01120093 · Phase 2
show 5 more results
0.032 vs -0.128 placebo L @ 6wk400 µg BID
NCT01462929 · Phase 3 · registry result, not featured evidence
0.174 vs -0.032 placebo L @ 2.142857142857143wk400 μg Bid
NCT00868231 · Phase 2 · registry result, not featured evidence
0.202 vs -0.06 placebo L @ 0.142857142857143wk400 μg Bid
NCT00868231 · Phase 2 · registry result, not featured evidence
0.047 vs -0.103 placebo L @ 1wk200 μg Bid
NCT01120093 · Phase 2
0.044 vs -0.103 placebo L @ 1wk100 μg Bid
NCT01120093 · Phase 2
FEV1 AUC(0-24h 0.133 vs -0.062 placebo L @ 1wk400 μg Bid
absolute change · L
NCT01120093 · Phase 2
show 5 more results
0.065 vs -0.085 placebo L @ 6wk400 µg BID
NCT01462929 · Phase 3 · registry result, not featured evidence
0.226 vs -0.006 placebo L @ 2.142857142857143wk400 μg Bid
NCT00868231 · Phase 2 · registry result, not featured evidence
0.211 vs -0.024 placebo L @ 0.142857142857143wk400 μg Bid
NCT00868231 · Phase 2 · registry result, not featured evidence
0.1 vs -0.062 placebo L @ 1wk200 μg Bid
NCT01120093 · Phase 2
0.088 vs -0.062 placebo L @ 1wk100 μg Bid
NCT01120093 · Phase 2
FEV1 Trough 0.048 L @ 52wk400 μg
absolute change · L
No placebo or comparator arm
NCT01045161 · Phase 3
show 3 more results
0.072 L @ 52wk400µg
NCT01044459 · Phase 3 · registry result, not featured evidence
0.029 L @ 52wk200 μg to 400 μg
NCT01045161 · Phase 3
0.034 L @ 52wk200µg
NCT01044459 · Phase 3 · registry result, not featured evidence
FEV1 Peak 0.172 L @ 52wk400 μg
absolute change · L
No placebo or comparator arm
NCT01045161 · Phase 3
show 3 more results
0.214 L @ 52wk400µg
NCT01044459 · Phase 3 · registry result, not featured evidence
0.176 L @ 52wk200 μg to 400 μg
NCT01045161 · Phase 3
0.185 L @ 52wk200µg
NCT01044459 · Phase 3 · registry result, not featured evidence
TDI Focal 56.9% (n=262) vs 45.5% (n=257) placebo @ 24wk400 μg Bid
responder rate · % of participants
Yes (% Patients with a 1-unit decrease)
NCT01001494 · Phase 3
show 1 more result
53.3% (n=270) vs 45.5% (n=257) placebo @ 24wk200 μg Bid
Yes (% Patients with a 1-unit decrease)
NCT01001494 · Phase 3
Moderate or Severe Exacerbation Rate Annualized 0.44 vs 0.57 placebo per year @ 52wk
event rate · per year
NCT01966107 · Phase 4
Exacerbation Hospitalization Rate Annualized 0.07 vs 0.1 placebo count @ 52wk
event rate · count
NCT01966107 · Phase 4

+ 25 further endpoints in the CSV export.

The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: Aclidinium bromide's landscape · Aclidinium bromide/formoterol fumarate's landscape